Month: September 2024

Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference

Written by Customer Service on September 23, 2024. Posted in Public Companies.

WALTHAM, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at Chardan’s 8th Annual Genetic Medicines Conference being held in New York on Monday, September 30, 2024 at 2:00 p.m. ET. A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation. About Dyne Therapeutics Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people...

Kaspi.kz to Announce 3rd Quarter and 9 Months 2024 Financial Results on 21st October

Written by Customer Service on September 23, 2024. Posted in Public Companies.

ALMATY, Kazakhstan, Sept. 23, 2024 (GLOBE NEWSWIRE) — Kaspi.kz (KSPI US) will report its financial results for the quarter and nine months ended September 30, 2024, on Monday, 21st October, 2024. On that day, management will hold a conference call and webcast at 8.00am EST (1pm GMT, 5.00pm Astana time) to review and discuss the company’s results for the period. 3rd Quarter & 9 months 2024 Financial Results Conference Call Monday, 21st October, 2024 To pre-register for this call, please go to the following link: https://www.netroadshow.com/events/login?show=ac66cfee&confId=71533 You will receive your access details via email. About Kaspi.kz Kaspi.kz’s mission is to improve people’s lives by developing innovative mobile products and services. To deliver upon this we operate a unique two-sided Super App model – Kaspi.kz...

Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer

Written by Customer Service on September 23, 2024. Posted in Public Companies.

– New data show istisociclib (KB-0742) triggered cell death in preclinical ovarian cancer models of platinum and PARP-inhibitor (PARPi) resistance – – New PK/PD results demonstrate that istisociclib given at 80mg on a 4 days on/3 days off schedule resulted in sustained downregulation of CDK9-dependent genes in peripheral blood mononuclear cells (PBMCs) – SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today highlighted new preclinical data from a study of istisociclib (KB-0742). The poster presentation took place over the weekend at the American Association for Cancer Research (AACR) 15th Biennial Ovarian Cancer Research Symposium. Kronos...

Jackson Health System projects 47% reduction in carbon emissions from patient monitors with Philips next generation monitoring platform

Written by Customer Service on September 23, 2024. Posted in Public Companies.

Jackson Memorial Health SystemPhilips MX550 IntelliVue Portable Bedside Patient Monitor with ShieldPhilips MX750, MX850, IntelliVue, Patient Monitors with ShieldOpportunity for significant savings in energy consumption, reduction of paper and elimination of disposable batteries for telemetry revealed in Life Cycle Assessment Amsterdam, The Netherlands and Cambridge, Mass. and Miami, FL. – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Jackson Health System, one of the nation’s largest public health systems in the United States, today announced results of a collaborative Life Cycle Assessment (LCA) measuring the sustainability impact of transitioning to Philips next generation monitoring solutions. The study was conducted at Jackson Memorial Hospital, Jackson North Medical Center...

Form 8.3 – ASCENTIAL PLC

Written by Customer Service on September 23, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: VELAY FINANCIAL SERVICES LTD(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. Not applicable(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree ASCENTIAL PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: Not applicable(e) Date position held/dealing undertaken: For...

Coherent to Demonstrate a Broad Portfolio of Innovative Products and Technologies at ECOC 2024

Written by Customer Service on September 23, 2024. Posted in Public Companies.

PITTSBURGH, Sept. 23, 2024 (GLOBE NEWSWIRE) — Coherent Corp. (NYSE: COHR), a global leader in optical communications components and subsystems, announced today that it will showcase its new products and technologies for next-generation optical communications networks at ECOC 2024 exhibition, September 23-25 at the Messe Frankfurt, Booth #A10. Coherent thought leaders will present at panels, technical sessions and workshops. RECENT PRODUCT ANNOUNCEMENTSIndustry’s First L-band 800G ZR/ZR+ Pluggable TransceiversL-band 800 Gbps coherent pluggable optical transceiver in QSFP-DD form factor allows hyperscalers and telecom carriers to expand fiber capacity at lower costs, moving from 32 Tbps to 64 Tbps capacity. First in the market to feature both C- and L-band wavelengths, Coherent 800G DCO transceivers offer high optical output power,...

Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering

Written by Customer Service on September 23, 2024. Posted in Public Companies.

NEWPORT BEACH, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) — Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a best-efforts offering, with no minimum amount of securities required to be sold. The offering is comprised of 28,571,425 shares of the Company’s common stock (or pre-funded warrants in lieu of shares of common stock). Each share of common stock or pre-funded warrant will be sold with one Series A Warrant to purchase one share of common stock at an exercise price of $0.38 per share (the “Series A Warrants”) and one Series B Warrant to...

Interim Results for the Six Months Ended 30 June 2024

Written by Customer Service on September 23, 2024. Posted in Public Companies.

Press release OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 Delivering Pure-Play CDMO Growth StrategyContinued execution of “One OXB” strategy with global integration progressing across UK, US and French operationsExisting near-term and medium-term financial guidance reiterated, supported by positive growth trajectory of the businessContinued strong demand for OXB’s CDMO services, with an increase in number of late stage programmesClient portfolio is maturing and now includes 37 clients and 48 programmes as of September 2024 (September 2023: 24 clients and 41 programmes), representing a growth of 54% for clients and 17% for programmes year-on-yearSuccessfully onboarded multiple new clients, including signing 7 early-stage AAV programmes in the USCurrently supporting late stage...

AITX Again Extends Commitment of No Reverse Stock Split

Written by Customer Service on September 23, 2024. Posted in Public Companies.

Company Continues to Demonstrate Continued Growth & Path to Operational Profitability Detroit, Michigan, Sept. 23, 2024 (GLOBE NEWSWIRE) — Artificial Intelligence Technology Solutions, Inc. (the “Company”) (OTCPK: AITX), a global leader in AI-driven security and productivity solutions, announces an extension of its commitment to not executing a reverse split before January 1, 2026, with two exceptions. The filing commits the Company to extend by one year its current ‘no reverse split’ corporate amendment. The current amendment was scheduled to expire on January 1, 2025. The commitment now extends to at least January 1, 2026, with two exceptions: the Company uplists to NASDAQ or the NYSE, or our authorized shares are reversed at the same rate as our outstanding shares. “While we have had no intention of conducting...

Hearing Aid Market to Witness 6.30% CAGR by 2031 | SkyQuest Technology

Written by Customer Service on September 23, 2024. Posted in Mergers And Acquisitions.

Hearing Aid Market size was valued at USD 8.72 billion in 2023 to USD 14.21 billion by 2031, growing at a CAGR of 6.30% during the forecast period (2024-2031). Westford, USA, Sept. 23, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that Hearing Aid Market will attain the value of USD 14.21 Billion by 2031, with a CAGR of 6.30% during the forecast period (2024-2031). The market is a technology-driven industry with new products including invisible, intelligent assistants, AI and Bluetooth controls. Companies are improving patient experience with new products and technologies, which they expect it will drive the market growth in the coming years. According to the National Institute of Deafness and Other Infectious Disorders. About 15% of the population have hearing loss. Government and regulatory support are projected to have a long-term...

Month: September 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals